About Semler
Semler Scientific, Inc. develops, manufactures and markets innovative products and services that support the early detection and treatment of chronic diseases.
Our flagship product, QuantaFlo®, is a patented, FDA-cleared point-of-care product that measures arterial blood flow in the extremities and provides results in a matter of minutes. QuantaFlo supports health care providers in the early diagnosis of vascular diseases, even in patients who are asymptomatic.
Our History of Accomplishments
2007
Dr. Herbert J. Semler cofounded Semler Scientific.
2010
Received FDA 510K clearance for first PAD system FloChec.
2015
Received FDA Clearance and ANSI Accreditation for QuantaFlo.
2016
Recognized in Deloitte's Technology Fast 500.
2018
Received HITRUST 9.1 Certification.
Reached milestone of 1,000,000 QuantaFlo Test Performed.
2020
Received HITRUST 9.2 Certification.
Introduced SemlerShield, SemlerVault, and SemlerAnalytics.
Recognized in Deloitte's Technology Fast 500 for Third Consecutive Year.
2021
Launched first ANAB Accredited Certificate Program for SemlerSimulation online Training.
2022
Received HITRUST 9.6 Certification.
Recognized in Forbes Top 100 Small-Cap List.
2023
Introduced Cloud-based computing for QuantaFlo Software.
2024
Introduced SemlerHub.
Semler Leadership
Doug Murphy-Chutorian - Interim Chief Executive Officer
Dr. Douglas Murphy-Chutorian currently serves as the Interim Chief Executive Officer of Semler Scientific, having previously served as CEO (October 2012-January 2026) and as a member of the Board of Directors (September 2012-January 2026). He has had a broad, diverse career in healthcare over the past 30 years in numerous positions including clinician, academician, inventor, entrepreneur, CEO, chairman of the board, and consultant to financial firms. From 2005 to 2012, he was the managing director of Select Healthcare Capital, LLC. Dr. Murphy-Chutorian is a named inventor on more than 30 patents and has guided more than 50 products through various regulatory approval processes. His business career has included extensive involvement in all facets of the medical industry from financial, research and development, manufacturing, marketing and sales, regulatory, reimbursement, and clinical trials. His breadth of healthcare experience includes all major sectors of the industry: medical devices, health services, pharmaceuticals, biotechnology, and managed care. Dr. Murphy-Chutorian received his B.A. and M.D. from Columbia University. He completed his internal medicine residency at New York University/Bellevue Medical Center and his fellowship in cardiology at Stanford University Medical Center. He has served as a faculty member in interventional cardiology at both Stanford and Montefiore Medical Centers.
Gena D. Parker - Chief Compliance Officer
Gena D. Parker serves as the Chief Compliance Officer. Gena joined Semler Scientific in January 2020 and has been responsible for developing and directing regulatory strategy, policies, and objectives from early-stage product development through the life cycle of medical device management. Additionally, Gena leads a team of quality and regulatory professionals in maintaining an effective framework for meeting audit and regulatory requirements. With over 25 years of experience in the Silicon Valley medical device industry, including 10 years at Phoenix DeVentures, her chief goal is creating and meeting the highest product quality standards while exceeding customer expectations.
Jennifer Oliva Herrington - Chief Operating Officer
Jennifer Oliva Herrington serves as Chief Operating Officer of Semler Scientific and President of CardioVanta, the company’s cardiovascular-focused business. In these roles, she has operating responsibility for the cardiovascular franchise, including technology strategy, product development, manufacturing, engineering, and business development, with accountability for execution across the entire business.
Ms. Herrington brings more than 25 years of experience leading regulated healthcare and medical technology organizations. Her background includes building and scaling operating platforms, translating clinical and technical innovation into commercial outcomes, and working closely with boards and executive leadership to drive disciplined growth and operational performance.
As COO of Semler Scientific and President of CardioVanta, Ms. Herrington serves as the senior operating executive for the cardiovascular business, setting strategy, allocating resources, and ensuring operational and commercial alignment in support of long-term value creation and improved cardiovascular outcomes.